share_log

Canopy Growth: Analyst Maintains Price Target Of $3.30, Stays Neutral After Q3 Results

Canopy Growth: Analyst Maintains Price Target Of $3.30, Stays Neutral After Q3 Results

Canopy Growth:分析師維持3.30美元的目標股價,在第三季度業績公佈後保持中立
Benzinga Real-time News ·  2022/11/10 06:41

Canopy Growth Corporation (NASDAQ:CGC) (TSX:WEED) recently reported its financial results for the third quarter that ended September 30, 2022 ("Q3 2022").

Canopy GROWT 納斯達克股票代碼:CGC)(多倫多證券交易所股票代碼:WEED)最近公佈了截至2022年9月30日的第三季度(“2022年第三季度”)的財務業績。

Cantor Fitzgerald's Pablo Zuanic said they stay Neutral on Canopy and maintain their 12-month price target of $3.30.

坎託·菲茨傑拉德的巴勃羅·祖亞尼奇 表示他們對Canopy保持中立,維持其12個月的目標股價爲3.30美元。

"Management called fiscal 2Q (Sep) an 'inflection point,' with Canada's cannabis sales starting to stabilize, and cash margins starting to improve (16%) on the back of savings and a shifting mix," he said in his latest analysis.

他在最新的分析中說:“管理層稱第二財季(9月)爲'轉折點',加拿大的大麻銷售開始穩定,現金利潤率開始提高(16%),這要歸因於儲蓄和結構的變化。”

The company's domestic medical business ($14.2Mn) was up 6% seq, and "we estimate it may be contributing as much to $ gross profits than recreational," Zuanic said. Regarding international sales ($10.5Mn), including U.S. CBD, "fell 24% seq. The CPG piece ($55Mn) was up 25% seq driven by hefty growth in BioSteel sports drinks (now 54% of CPG)," he added.

該公司的 國內醫療業務 Zuanic說,(1420萬美元)連續增長6%,“我們估計,它對毛利的貢獻可能與娛樂業一樣多。”關於包括美國中央商務區在內的國際銷售額(1,050萬美元),“連續下降24%。在BioSteel運動飲料(現佔CPG的54%)大幅增長的推動下,CPG股票(5500萬美元)連續上漲25%,” 他補充說。

The company's total adjusted EBITDA of ~-$78Mn was only slightly worse than the June quarter (~-$75Mn).

該公司調整後的息稅折舊攤銷前利潤總額約爲-7,800萬美元,僅略低於6月季度(約-7500萬美元)。

Additionally, management is guiding for "$30-50Mn of COGS savings to mostly kick in by fiscal 2H23, and $70-100Mn in SGA savings to be realized in the next 12-18 months."

此外,管理層預計 “到23財年下半年,將主要節省3000萬至5000萬美元的COGS,並在未來12-18個月內節省7000萬至1億美元的SGA。”

Canopy USA Structure

Canopy USA 結構

Zuanic noted that the Canopy USA structure is "expected to be completed within the next 9-12 months, and by then the company's global cannabis business would be profitable.

Zuanic指出,Canopy USA的結構 “預計將在未來9-12個月內完成,屆時該公司的全球大麻業務將實現盈利。

"With the stock up more than 40% since 10/24, following the Canopy USA structure announcement, clearly, sentiment is being driven by the company's ability to close on these deals."

“在Canopy USA宣佈結構之後,該股自10月24日以來上漲了40%以上,很明顯,市場情緒是由該公司完成這些交易的能力所推動的。”

Zuanic expects "shareholders of the three companies to vote in favor and regulatory approval to be completed sometime in 2H23; at that point, the company will need to decide whether it remains listed on the NASDAQ or only on the TSX...or find an agreement with auditors and other regulators to close on the deals but not consolidate them pending final NASDAQ acceptance of the consolidation of the Canopy USA structure."

Zuanic 預計“這三家公司的股東將投贊成票,監管部門的批准將在23年下半年的某個時候完成;屆時,該公司將需要決定是否繼續在納斯達克上市還是僅在多倫多證券交易所上市... 或者與核數師和其他監管機構達成協議,以完成交易,但在納斯達克最終接受Canopy USA結構的合併之前不進行合併。”

Having introduced a new proforma model, Cantor's analysts reported that they will now take a more earnings-based approach. "Our approach yields a 12-month price target of $3.30."

引入了 新的形式模型,坎託的分析師報告說,他們現在將採取更加基於收益的方法。“我們的方法使12個月的目標股價爲3.30美元。”

Finally, on the valuation side, the recent rise in the stock has resulted in the company's piece of cannabis (no US THC) being valued at 6.9x CY23E sales vs. 1-4x for most of the group, but "we realize this is partly distorted by the fact we are only taking the U.S. assets at acquisition value," Zuanic concluded.

最後,在估值方面, Zuanic總結說,最近該股的上漲使該公司的大麻(不包括美國四氫大麻酚)的價值爲 CY23E 銷售額的6.9倍,而該集團大部分公司的銷售額爲1-4倍,但是 “我們意識到這在一定程度上被扭曲了,因爲我們只按收購價值收購美國資產。”

Get your daily dose of cannabis news on Benzinga Cannabis. Don't miss out on any important developments in the industry.

在 Benzinga Cannabis 上獲取每日劑量的大麻新聞。不要錯過該行業的任何重要發展。

Photo: Courtesy of Nicholas Cappello On Unsplash

照片:由尼古拉斯·卡佩洛提供 On Unsplash

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論